Biohaven reported a net loss of 145555000 for Q4 2025 as the company advanced key late-stage programs while implementing cost optimization measures. R&D expenses declined year-over-year to 121945000, and cash, cash equivalents and marketable securities totaled 319137000 at quarter end.

Biohaven posted a Q2 2025 net loss of $198.147M (−$1.94 EPS) on no revenue, with R&D and G&A expenses totaling $211.7M. Non-GAAP adjusted net loss was $166.365M (−$1.63 EPS). The company ended the quarter with $165.8M in cash and equivalents, and $408.2M in combined cash, marketable securities, and restricted cash, while progressing multiple late-stage clinical programs.

Biohaven reported a net loss of $186.8 million for Q4 2024, with R&D expenses increasing to $167.5 million. The company announced FDA acceptance and Priority Review for troriluzole NDA and positive degrader data for BHV-1300, while maintaining a strong cash position.

Biohaven reported a net loss of $160.3 million, or $1.70 per share, for the third quarter ended September 30, 2024. The company achieved positive topline results from a pivotal trial with troriluzole in spinocerebellar ataxia (SCA) and initiated a Phase 2 trial evaluating BHV-2100 in the acute treatment of migraine.

Biohaven reported a net loss of $319.8 million, or $3.64 per share, for the second quarter ended June 30, 2024. The company's cash, cash equivalents, marketable securities and restricted cash totaled approximately $440 million on June 30, 2024. Biohaven is advancing its pipeline with multiple clinical trials underway and expects several milestones in 2024 and 2025.

Biohaven reported a net loss of $179.5 million, or $2.20 per share, for the first quarter ended March 31, 2024. The company's cash, cash equivalents, marketable securities, and restricted cash totaled approximately $287.6 million as of March 31, 2024, excluding net proceeds from a public offering completed in April 2024. Biohaven is advancing its pipeline with multiple clinical trials underway and INDs planned for its MoDE platform.

Biohaven reported a net loss of $144.8 million, or $1.81 per share, for the three months ended December 31, 2023. The company is focused on advancing its clinical programs across five platforms and expects to deliver potentially groundbreaking data across three distinct programs.

Biohaven reported a net loss of $102.6 million for the third quarter of 2023. The company's cash, cash equivalents, marketable securities, and restricted cash totaled approximately $495 million as of October 5, 2023, including net proceeds of $242 million from a public offering.

Biohaven reported a net loss of $90.3 million for the second quarter of 2023. The company highlighted positive interim data from its BHV-7000 EEG biomarker study and the advancement of BHV-8000 into Phase 1 clinical trials. They also plan to submit an IND for BHV-1300 in the second half of 2023.

Biohaven reported a net loss of $70.5 million, or $1.03 per share, for the first quarter of 2023. The company is advancing its pipeline of therapies for neurological and neuropsychiatric diseases and expects to reach significant pipeline milestones in the coming periods.

Biohaven Ltd. reported a net loss of $201.1 million for the three months ended December 31, 2022. As of December 31, 2022, the company had cash and equivalents of $465.3 million and no debt. The company is focused on advancing its pipeline of therapies for neurological and neuropsychiatric diseases.

Biohaven Ltd. reported a net loss of $68.9 million, or $1.75 per share, for the three months ended September 30, 2022. The company launched as a new publicly traded company in October and raised gross proceeds of approximately $301.9 million in a public financing.